Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting
November 01 2018 - 9:05AM
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced an upcoming poster presentation at the 2018
American Society of Hematology (ASH) Annual Meeting and Exposition,
taking place from December 1-4, 2018 in San Diego, CA. In addition,
ASH abstracts will appear in the November supplemental issue of
Blood.
Dr. Maro Ohanian, Assistant Professor of the Department of
Leukemia at The University of Texas MD Anderson Cancer Center, will
present interim data from the ongoing Phase 2 trial of
prexigebersen (BP1001), the Company’s lead drug candidate, for the
treatment of acute myeloid leukemia. Co-author Dr. Ana Tari
Ashizawa, Vice President of Research and Development at Bio-Path,
will also be available at the poster presentation.
Details for the presentation are as follows:
Date: Saturday, December 1,
2018Presentation Time: 6:15 PM - 8:15 PM Pacific
TimeLocation: San Diego Convention Center, Hall
GHSession Name: 613. Acute Myeloid Leukemia:
Clinical Studies: Poster ITitle: Interim Safety
and Efficacy of Lower Intensity Induction Therapy with Intravenous
Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid
Leukemia (AML)
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s lead product candidate, prexigebersen
(BP1001, targeting the Grb2 protein), is in a Phase 2 study for
blood cancers and in preclinical studies for solid tumors. This is
followed by BP1002, targeting the Bcl-2 protein, which the company
anticipates entering into clinical studies where it will be
evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Contact Information:
Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc.832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Apr 2024 to May 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From May 2023 to May 2024